Empagliflozin inhibits Na(+)/H(+) exchanger activity in human atrial cardiomyocytes

AIMS: Recent clinical trials have proven gliflozins to be cardioprotective in diabetic and non‐diabetic patients. However, the underlying mechanisms are incompletely understood. A potential inhibition of cardiac Na(+)/H(+) exchanger 1 (NHE1) has been suggested in animal models. We investigated the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Trum, Maximilian, Riechel, Johannes, Lebek, Simon, Pabel, Steffen, Sossalla, Samuel T., Hirt, Stephan, Arzt, Michael, Maier, Lars S., Wagner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755005/
https://www.ncbi.nlm.nih.gov/pubmed/32946200
http://dx.doi.org/10.1002/ehf2.13024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755005/
https://www.ncbi.nlm.nih.gov/pubmed/32946200
http://dx.doi.org/10.1002/ehf2.13024

Ejemplares similares